Shanghai yingli pharmaceutical

Author: roll

August undefined, 2024

WebbShanghai YingLi Pharmaceutical Co. Ltd. 2024-05-07 Phase 2 A Phase 2, Single Arm, Open Label Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of … Webb24 jan. 2024 · No New Molecular Entity Yes Highest Development Phases Phase II Gout; Hyperuricaemia Most Recent Events 24 Jan 2024 YL 90148 is still in phase II clinical trial in Gout and Hyperuricaemia in China (Shanghai Yingli Pharmaceutical pipeline, January 2024) ; 23 Dec 2024 Phase-II clinical trials in Gout in China (PO) (Shanghai Yingli …

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed …

Webb5 nov. 2024 · 11 Shanghai Yingli Pharmaceutical Co.,Ltd, Shanghai, China. Search for other works by this author on: This Site. PubMed. Google Scholar. Fei Li, Fei Li 12 The First Affiliated Hospital of Nanchang University, Nanchang, China, China. Search for other works by this author on: This Site. PubMed. Webb28 maj 2024 · Toxicities with Linperlisib therapy were generally tolerable and manageable. Further efficacy and safety is being evaluated. Clinical trial information: NCT04108325. © 2024 by American Society of Clinical Oncology Research Sponsor: Shanghai Yingli Pharmaceutical Co., Ltd dew kaitlyn bristow

Shanghai Yingli Pharmaceutical - Overview, News & Competitors ...

Webb璎黎药业抗癌新药林普利塞（商品名：因他瑞®）获批上市中国首个高选择性pi3kδ抑制剂 Webb29 apr. 2024 · Shanghai YingLi Pharmaceutical Co. Ltd. Provider of Information About this Clinical Study Sponsor; Overall Contact(s) Hanying Bao, MD,PhD, 86 21-51370693, [email protected]; Conditions in This Trial. Follicular Lymphoma; Interventions in This Trial. YY-20394; Condition MeSH Term(s) Webb14 apr. 2024 · Pharmacologic inhibition of the δ isoform of PI3K (PI3Kδ) reduces proliferation, migration, and survival of the malignant B-cell leukemia and lymphoma cells. The novel orally active PI3Kδ inhibitor linperlisib has shown a notable efficacy in B-cell lymphomas, especially for a FL subgroup, in a previous phase I study. dewland photography

Yingli Pharma announce promising topline results of a Phase II ...

Webb1 apr. 2024 · SHANGHAI, March 31, 2024 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3Kδ inhibitor, for ... Webb1 mars 2024 · Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase II drugs for Anaplastic Large Cell Lymphoma (ALCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. church services tv romileyWebb14 okt. 2024 · Shanghai Yingli Pharmaceutical Co., Ltd. (YL-15293), Lingji Biological, Luye Pharmaceutical, Deqi Pharmaceutical (ATG-012), Guangdong Xinqi Biomedicine, Haibowei, Hangzhou Duoyu, Enrui Biological, China Pharmaceutical University, PhD, etc. In addition, there are some companies under research that have not been made public. church services tv newry cathedral

"Webb4 juni 2024 · Yingli Pharma, headquartered in Shanghai with a subsidiary in San Francisco, is an innovative clinical stage biopharmaceutical company. Yingli Pharma is developing best-in-class and first-in-class oral investigational agents for the treatment of cancer, metabolic and autoimmune diseases. " - Shanghai yingli pharmaceutical

Shanghai yingli pharmaceutical

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed …

Webb8 mars 2024 · DOI: 10.1200/JCO.22.01794 Journal of Clinical Oncology - published online before print March 8, 2024 . PMID: 36888930 Webb9 nov. 2024 · SHANGHAI, CHINA - Media OutReach - 9 November 2024 - Shanghai Yingli Pharmaceutical Co., Ltd. (the "Company" or "Yingli Pharma") is pleased to announce that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China on …

Did you know?

Webb9 nov. 2024 · Shanghai Yingli Pharmaceutical Co., Ltd. is a technologically innovative biopharmaceutical company founded in 2011 and located in the National Biomedical Industry Base of Shanghai Zhangjiang ... Webb1 juli 2024 · Abstract. TGF-beta (TGF-β) pathways, despite serving as tumor suppressor in early stage of carcinogenesis, have shown be one of the key tumor-promoting factors in later-stage tumor progression. TGF-β receptor I kinase (TGF-βR1) inhibitors have shown great potentials in their anti-tumor and anti-metastasis efficacy in preclinical studies and …

WebbShanghai Yingli Pharmaceutical overview. Shanghai Yingli Pharmaceutical (Yingli) is a pharmaceutical company focused on discovery and development of innovative small … WebbRelying on the abundant Marine resources in Southeast Asia, Yingli Chemical (Shanghai) Co., Ltd. is engaged in the processing and research and development of six series of industrial salt, bromine, bromine inorganic salts, flame retardants, fungicides, cleaning agents, pharmaceutical pesticides and chemical intermediates.In addition, the Shanghai …

Webb30 Dec 2024 Shanghai Yingli Pharmaceutical plans a phase I/II trial for Solid tumors (Late-stage disease, Metastatic disease) (PO) (NCT05173805) 09 Nov 2024 Phase-I/II clinical … Webb6 apr. 2024 · SP-02: Solasia Pharma SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers.

Webb4 juni 2024 · Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, ... SHANGHAI and SAN FRANCISCO, June 4, 2024 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd ...

WebbClinical Trials Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd. Total 16 results. NCT05457517 Recruiting A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors. Advanced … dewlance hosting reviewsWebb1 apr. 2024 · Yingli Pharma, a clinical stage innovative biopharmaceutical company, is developing best-in-class and first-in-class oral investigational agents for the treatment of … dewk thermo-hygrometerWebb28 feb. 2024 · At a glance Originator Shanghai Yingli Pharmaceutical Developer Jiangsu Hengrui Medicine Co.; Shanghai Yingli Pharmaceutical Class Antineoplastics; Morpholines; Piperidines; Pyridines; Quinazolines; Small molecules; Sulfonamides Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors Orphan Drug Status church services tv sacred heart corkhttp://www.yl-pharma.com/cn/index.html dewlahland pin codeWebb3 sep. 2024 · SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Yingli Pharma (the "Company" or "Yingli"), a clinical stage biotechnology company developing oral small molecule drugs for cancers with high unmet... dew land productionsWebb28 juni 2024 · 企查查为您提供上海康景生物医药科技有限公司的最新工商信息、公司简介、公司地址、电话号码、招聘信息、信用信息、财务信息、法律诉讼等多维度详细信息查询，让您对上海康景生物医药科技有限公司能够做到全面的了解！ dewlands black notleyWebbShanghai Yingli Pharmaceutical Co Ltd is a company that operates in the Pharmaceuticals industry. It employs 6-10 people and has $1M-$5M of revenue. The company is headquartered in Shanghai, Shanghai, China. Read More Contact Who is Shanghai Yingli Pharmaceutical Headquarters church services tv waltham cross